View Document Preview and Link Document Date: 2014-12-04 01:34:29 Open Document File Size: 69,67 KB Share Result on Facebook
City Lille / / Company Université de Lille 2 / The Wellcome Trust / GlaxoSmithKline Basel / BioVersys / / Country Switzerland / France / / Currency GBP / / / Event Business Partnership / / Facility University of Lille / The University / About University / / IndustryTerm biopharmaceutical / pharmaceutical laboratories / / MedicalCondition TB / bacterial infections / disease / neglected disease / Mycobacterium tuberculosis / active TB / threat Tuberculosis / diseases / Nosocomial Infections / hospital infections / infectious disease / potent tuberculosis / tuberculosis / / MedicalTreatment antibiotics / innovative therapies / / Organization Centre National / World Health Organization / About The Wellcome Trust The Wellcome Trust / University of Lille / Institut Pasteur de Lille / Institut National / / Person Marc Gitzinger / Professors Nicolas Willand / Benoît Deprez / Alain Baulard / Xavier Vandendriessche / Daniel Piller / / / Position CEO / Professor / President / / Technology drug discovery / TRIC technology / / URL www.irfcom.ch / www.wellcome.ac.uk / www.bioversys.com / / SocialTag 
SWITCHING OFF BACTERIAL RESISTANCE BioVersys and Université de Lille achieve first milestone in tuberculosis collaboration with GlaxoSmithKline Basel (Switzerland), and Lille (France), December[removed] – BioVersys tog